Neurocrine Biosciences (NBIX) Competitors $132.02 -2.09 (-1.56%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$131.99 -0.03 (-0.03%) As of 07/18/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, INCY, UTHR, EXEL, BMRN, EXAS, HALO, MDGL, and RGENShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Do analysts prefer NBIX or ALNY? Neurocrine Biosciences presently has a consensus price target of $163.91, indicating a potential upside of 24.15%. Alnylam Pharmaceuticals has a consensus price target of $346.13, indicating a potential upside of 7.99%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.87Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor NBIX or ALNY? In the previous week, Neurocrine Biosciences had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 37 mentions for Neurocrine Biosciences and 30 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.61 beat Neurocrine Biosciences' score of 0.28 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 11 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 10 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Which has higher earnings & valuation, NBIX or ALNY? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.36B5.55$341.30M$2.9544.75Alnylam Pharmaceuticals$2.25B18.59-$278.16M-$2.09-153.36 Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 12.68% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Neurocrine Biosciences' return on equity of 11.81% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences12.68% 11.81% 8.59% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% Do institutionals & insiders hold more shares of NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 1.2% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.07B$2.43B$5.51B$9.40BDividend YieldN/A1.80%4.00%4.04%P/E Ratio44.758.8228.2019.77Price / Sales5.55712.02413.3488.91Price / Cash39.0622.4924.9928.17Price / Book5.165.008.155.69Net Income$341.30M$30.99M$3.25B$257.97M7 Day Performance-2.30%0.46%0.42%1.92%1 Month Performance4.32%10.07%7.75%12.82%1 Year Performance-9.38%0.90%33.65%19.22% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.46 of 5 stars$132.02-1.6%$163.91+24.2%-9.4%$13.07B$2.36B44.751,800Trending NewsALNYAlnylam Pharmaceuticals4.0129 of 5 stars$315.75+0.3%$345.70+9.5%+34.8%$41.17B$2.25B-151.082,230BIIBBiogen4.9331 of 5 stars$133.11-0.8%$188.48+41.6%-44.8%$19.50B$9.68B13.147,605Trending NewsINCYIncyte4.5445 of 5 stars$69.98+2.0%$74.47+6.4%+3.0%$13.55B$4.24B218.692,617UTHRUnited Therapeutics4.9862 of 5 stars$297.68+0.7%$383.08+28.7%-11.3%$13.43B$2.88B11.881,305Positive NewsEXELExelixis4.8133 of 5 stars$45.58+1.6%$45.22-0.8%+96.8%$12.43B$2.17B20.721,147BMRNBioMarin Pharmaceutical4.9885 of 5 stars$58.23+0.2%$93.78+61.1%-31.9%$11.17B$2.85B21.653,040Positive NewsAnalyst DowngradeAnalyst RevisionEXASExact Sciences4.7147 of 5 stars$54.30+4.6%$70.50+29.8%+7.8%$10.24B$2.76B-9.857,000Positive NewsHALOHalozyme Therapeutics4.9593 of 5 stars$57.65+0.9%$62.50+8.4%+4.5%$7.10B$1.02B15.33390Positive NewsMDGLMadrigal Pharmaceuticals4.2623 of 5 stars$319.87+1.4%$420.63+31.5%+16.3%$7.10B$180.13M-17.7290Trending NewsInsider TradeRGENRepligen4.6781 of 5 stars$121.33-6.8%$170.75+40.7%-6.1%$6.82B$650.43M-269.621,778Analyst Revision Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors Incyte Competitors United Therapeutics Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
